Copy



 

 

Two Major Deals Announced, Don’t Miss Access to Innovation Tomorrow

It has been an exciting and busy start to 2019, with the announcement of two major deals by our valued clients and portfolio companies. AIT Therapeutics, closed a $32.5M medical device distribution licensing agreement for Pulmonary Hypertension for the US and China, and Phoenix Molecular Designs, announced a development partnership with Roche Diagnostics.

With the ACCESS TO INNOVATION conference set to take place in Vancouver tomorrow, we explore the importance of collaboration and knowledge sharing in today's rapidly evolving life sciences sector.

We are actively seeking seasoned corporate and development Life Science Executives for our clients. Please reach out to us via our website.

FOR MORE INFO CLICK HERE

 
CLIENT DEALS, PARTNERSHIPS 2019

As Senior Vice President, Device and Business Development at AIT Therapeutics, I was pleased to consummate a distribution and commercialization deal with Circassia Pharmaceuticals.

AIT Therapeutics, announced the $32.5M and double digit commercial licensing agreement with Circassia for its Novel Nitric Oxide Generator and Delivery System for use in the hospital setting in the United States and China.

FOR MORE INFO CLICK HERE

“Novateur’s vast and knowledgeable advisors have been instrumental in enabling our success in development and commercialization of our pipeline, fundraising and partnership. We highly recommend them.”

Amir Avniel
Co-Founder, COO & President, AIT Therapeutics


 

On January 16, 2019 our valued client and portfolio investment company, Phoenix Molecular Designs, announced a collaboration with Roche to develop a diagnostic (CDx) in triple-negative breast cancer (TNBC).

FOR MORE INFO CLICK HERE

"The Novateur Team has accelerated our development path far beyond our initial expectations. They are highly responsive and truly know how to create value in companies."

Dr. Sandra Dunn
CEO, Phoenix Molecular Designs

read more
Why attending the
ACCESS TO INNOVATION
Conference is more important than ever?
As we begin 2019, we are at intersection of significant new advances for health care development and delivery. More than ever, we are seeing possibility of accessing innovative solutions for health care through digital health. Global technology companies such as Amazon, Microsoft and Google are now looking on delivering and optimizing health care as their next challenge. New breakthrough therapies are becoming possible harnessing mining and interpreting large amount of data via artificial intelligence. Medicinal cannabis has opened an ocean of possibility for new treatments for various ailments.

For the 4th year now, ACCESS TO INNOVATION is bringing together our life science community to discuss and provide meaningful ways to collaborate, deliver innovation and engage with the intention of improving patient-care outcomes, while impacting cost saving measures. We have realized that over the history of this conference, that only by working together, can we succeed.

New partnerships and collaborations at both global and local level have blurred the boundaries between providers.

British Columbia, with a history of impressive health research and medical innovation, is globally poised to become a health and scientific centre of excellence. We now sit at the crossroads of an incredible opportunity to adopt a transformative innovation agenda; thereby accelerating the province’s ecosystem of health research, delivery and policy, to a position of influence not only here, but around the world.

Access to Innovation 2019 is constructed to guide, advance and to transform momentum into action.

During this conference we will; explore the future of human life sciences’ discovery locally, nationally and internationally; recognize discovery and innovation in healthcare systems; identify key trends driving disruption; while characterizing essential steps to keep B.C. not only in lockstep but setting the pace for global innovation ecosystems.

This is one conference not to miss. We look forward to seeing you on Wednesday.

Nancy Harrison,
Chair, LifeSciences BC

Ali Ardakani,
Vice Chair, LifeSciences BC
read more & register here
watch a video to learn about the conference
DRUG DEVELOPMENT
EXECUTIVE ADVISORY SUITE
Working with clients to overcome pharmaceutical development challenges from discovery to commercialization.
Lloyd Mackenzie
Product Development Lead

(Aquinox, QLT, Inflazyme)
Patrick Tam, PhD
Pre-clinical Development Lead
(Aquinox, Forbes Medi-Tech)
Daniela Nenciu, RPh, RAC
Therapeutics Regulatory Lead
(Aquinox, Allon Therapeutics, Medochemie)
Pina Kingman, MSc
Medical Marketing & Communications Lead
(Medmovie)
Marion Lorden, PMP
Program Manager
(BTG, Nordion)


 
 


UPCOMING EVENTS

Novateur Executives will be attending these upcoming events. Reach out and meet with us.






LifeSciences BC
Access to Innovation 2019

January 30, 2019 — Vancouver, BC

Join us for the 4th annual LifeSciences BC Access to Innovation Conference at the Vancouver Convention Centre West from 8:00 AM – 7:00 PM PST.

Stakeholders include: Academia, Health Institutions, Government, Centres of Innovation, SMEs, Multi-national Corporates, Investors and Payers.

MORE INFO



 

 

21st Annual LifeSciences BC Awards Dinner Presented b Farris
April 4, 2019 — Vancouver, BC

MORE INFO

BIO International Convention 2019
June 3-6, 2019 - Philadelphia, PA

MORE INFO
 

+1 844 200 6682
Toll free USA & Canada
download our presentation
Copyright © 2019 Novateur Ventures Inc., All rights reserved.


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.